BETA Technologies launches IPO of 25 million shares priced $27-$33
Investing.com -- Abbott Laboratories shares slid over 2% in premarket trading Wednesday after the medical devices maker reported in-line third-quarter earnings and sales just shy of the consensus forecast.
The company posted earnings per share (EPS) of $1.30, matching estimates. Revenue came in at $11.37 billion, slightly below the $11.4 billion consensus forecast.
Sales rose 6.9% on a reported basis and 5.5% organically, with growth improving to 7.5% when excluding COVID-19 testing-related revenue.
"Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance," said Robert Ford, chairman and CEO of Abbott. "Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders."
For the full year 2025, Abbott guided for earnings of $5.12 to $5.18 per share, compared with the current consensus estimate of $5.14.
The company maintained its outlook for organic sales growth of 7.5% to 8.0% excluding COVID-19 testing impacts, or 6.0% to 7.0% when those testing revenues are included.